9.11
9.11 (0%)
As of Apr 17, 2025
Amarin Corp Plcuk [AMRN]
Source:
Company Overview
Amarin Corp Plcuk is a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Our commercialized product, VASCEPA was first approved by the United States, or U.S., Food and Drug Administration, or U.S. FDA, for use as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe hypertriglyceridemia, or the MARINE indication, and commercially launched in 2013.
| Country | United States |
| Headquarters | dublin 2 |
| Phone Number | 353 1 6699 020 |
| Industry | manufacturing |
| CEO | Patrick Holt |
| Website | www.amarincorp.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $228.6 |
| Operating Profit | $-91.8 |
| Net Income | $-82.2 |
| Net Cash | $-78.4 |
Profit Ratios
| Gross Margin | $81.4 |
| Operating Margin | -40.2 |
| Profit as % of Revenues | -99% |
| Profit as % of Assets | -10.8% |
| Profit as % of Stockholder Equity | -16.9% |
Management Effectiveness
| Return on Equity | -16.9% |
| Return on Assets | -12% |
| Turnover Ratio | 30.1% |
| EBITA | $-91.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $685.3 |
| Total Liabilities | $199.2 |
| Operating Cash Flow | $-31 |
| Investing Cash Flow | $-46 |
| Financing Cash Flow | $-1.4 |
